Patents by Inventor Alessandro Consonni

Alessandro Consonni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cloning, yeast expression, purification and biological activity of the extension region of the soybean 7S globulin alfa' subunit involved in HEP G2 cell cholesterol homeostasis
    Patent number: 8569455
    Abstract: A truncated form of ?? chain (e??), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the N-terminal extension region of the soybean alpha? subunit. The e?? polypeptide was purified by conventional biochemical techniques and its potential to modulate the activity of the LDL-receptor was evaluated in a human hepatoma cell line (Hep G2) by monitoring the uptake and degradation of labeled LDL.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: October 29, 2013
    Assignee: Indena S.p.A.
    Inventors: Paolo Morazzoni, Antonella Riva, Cesare Ponzone, Davide Berlanda, Marcello Duranti, Alessandro Consonni
  • CLONING, YEAST EXPRESSION, PURIFICATION AND BIOLOGICAL ACTIVITY OF THE EXTENSION REGION OF THE SOYBEAN 7S GLOBULIN ALFA' SUBUNIT INVOLVED IN HEP G2 CELL CHOLESTEROL HOMEOSTASIS
    Publication number: 20120172316
    Abstract: A truncated form of ?? chain (e??), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the N-terminal extension region of the soybean alpha? subunit. The e?? polypeptide was purified by conventional biochemical techniques and its potential to modulate the activity of the LDL-receptor was evaluated in a human hepatoma cell line (Hep G2) by monitoring the uptake and degradation of labeled LDL.
    Type: Application
    Filed: June 16, 2010
    Publication date: July 5, 2012
    Applicant: INDENA S.P.A.
    Inventors: Paolo Morazzoni, Antonella Riva, Cesare Ponzone, Davide Berlanda, Marcello Duranti, Alessandro Consonni